• Title of article

    Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE study

  • Author/Authors

    Robert Stingele، نويسنده , , Jürgen Berger PhD، نويسنده , , Karsten Alfke، نويسنده , , Hans-Henning Eckstein، نويسنده , , Gustav Fraedrich، نويسنده , , Jens Allenberg، نويسنده , , Marius Hartmann، نويسنده , , Peter A. Ringleb، نويسنده , , Jens Fiehler and for the SPACE investigators، نويسنده ,

  • Issue Information
    روزنامه با شماره پیاپی سال 2008
  • Pages
    7
  • From page
    216
  • To page
    222
  • Abstract
    Summary Background Carotid endarterectomy (CEA) and carotid artery stenting (CAS) are used to prevent ischaemic stroke in patients with stenosis of the internal carotid artery. Better knowledge of risk factors could improve assignment of patients to these procedures and reduce overall risk. We aimed to assess the risk of stroke or death associated with CEA and CAS in patients with different risk factors. Methods We analysed data from 1196 patients randomised to CAS or CEA in the Stent-Protected Angioplasty versus Carotid Endarterectomy in Symptomatic Patients (SPACE) trial. The primary outcome event was death or ipsilateral stroke (ischaemic or haemorrhagic) with symptoms that lasted more than 24 h between randomisation and 30 days after therapy. Six predefined variables were assessed as potential risk factors for this outcome: age, sex, type of qualifying event, side of intervention, degree of stenosis, and presence of high-grade contralateral stenosis or occlusion. The SPACE trial is registered at Current Controlled Trials, with the international standard randomised controlled trial number ISRCTN57874028. Findings Risk of ipsilateral stroke or death increased significantly with age in the CAS group (p=0•001) but not in the CEA group (p=0•534). Classification and regression tree analysis showed that the age that gave the greatest separation between high-risk and low-risk populations who had CAS was 68 years: the rate of primary outcome events was 2•7% (8/293) in patients who were 68 years old or younger and 10•8% (34/314) in older patients. Other variables did not differ between the CEA and CAS groups. Interpretation Of the predefined covariates, only age was significantly associated with the risk of stroke and death. The lower risk after CAS versus CEA in patients up to 68 years of age was not detectable in older patients. This finding should be interpreted with caution because of the drawbacks of post-hoc analyses
  • Journal title
    Lancet Neurology
  • Serial Year
    2008
  • Journal title
    Lancet Neurology
  • Record number

    802142